PMID- 19207950
OWN - NLM
STAT- MEDLINE
DCOM- 20090430
LR  - 20191210
IS  - 1365-2559 (Electronic)
IS  - 0309-0167 (Linking)
VI  - 54
IP  - 2
DP  - 2009 Jan
TI  - Evaluation of automated silver-enhanced in situ hybridization (SISH) for 
      detection of HER2 gene amplification in breast carcinoma excision and core biopsy 
      specimens.
PG  - 248-53
LID - 10.1111/j.1365-2559.2008.03185.x [doi]
AB  - AIMS: To validate the use of the silver-enhanced in situ hybridization (SISH) 
      technique in assessing HER2 status of breast carcinoma in excision biopsy 
      specimens, and to assess its reliability in determining HER2 status in core 
      biopsy specimens. METHODS AND RESULTS: Routinely processed paraffin sections of 
      65 excised breast carcinomas and 56 available preoperative core biopsy specimens 
      from the same patients were selected from the archives for testing with the SISH 
      technique using the automated Ventana Benchmark XT machine. For each case, two 
      sections were used, one for the assessment of HER2 gene amplification and the 
      other for assessment of chromosome 17. Of the 65 excision specimens tested, 
      sections of 53 cases were also available for fluorescence in situ hybridization 
      (FISH) examination. HER2 gene amplification was detected by SISH in 14 (21%) out 
      of 65 excision specimens and in eight (14%) out of 56 core biopsy specimens. The 
      results of SISH and FISH were identical in 50 (94%) out of the 53 excision cases 
      examined by the two techniques. Two cases were SISH-, FISH+, and one case was the 
      other way round. SISH results of core biopsy specimens and corresponding excision 
      biopsy specimens were identical in 50 (89%) out of 56 cases. Four cases (7%) were 
      SISH- in cores but positive in excision specimens, whereas two cases were the 
      other way round. CONCLUSIONS: The results validate the use of the SISH technique 
      for assessing HER2 status of excised breast carcinoma tissue sections. The 
      results are comparable to those obtained with FISH, but SISH has the advantage of 
      having a permanent end result that can be visualized by an ordinary light 
      microscope. There is a reasonable 89% concordance between SISH results obtained 
      in core and excision biopsy specimens. However, it may be prudent to postpone 
      doing SISH, if possible, until sections of the resected specimen are available, 
      as these seem to be more reliable.
FAU - Shousha, S
AU  - Shousha S
AD  - Department of Histopathology, Charing Cross Hospital, Imperial College Healthcare 
      NHS Trust, London, UK. s.shousha@imperial.ac.uk
FAU - Peston, D
AU  - Peston D
FAU - Amo-Takyi, B
AU  - Amo-Takyi B
FAU - Morgan, M
AU  - Morgan M
FAU - Jasani, B
AU  - Jasani B
LA  - eng
PT  - Journal Article
PT  - Validation Study
PL  - England
TA  - Histopathology
JT  - Histopathology
JID - 7704136
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Automation
MH  - Biopsy, Needle
MH  - Breast Neoplasms/*genetics/surgery
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - In Situ Hybridization/*methods
MH  - In Situ Hybridization, Fluorescence
MH  - Nucleic Acid Amplification Techniques/*methods
MH  - Receptor, ErbB-2/*genetics
MH  - Silver Staining/*methods
EDAT- 2009/02/12 09:00
MHDA- 2009/05/01 09:00
CRDT- 2009/02/12 09:00
PHST- 2009/02/12 09:00 [entrez]
PHST- 2009/02/12 09:00 [pubmed]
PHST- 2009/05/01 09:00 [medline]
AID - HIS3185 [pii]
AID - 10.1111/j.1365-2559.2008.03185.x [doi]
PST - ppublish
SO  - Histopathology. 2009 Jan;54(2):248-53. doi: 10.1111/j.1365-2559.2008.03185.x.